Adam Abate

Fluent BioSciences, Inc. is a privately funded biotechnology company based in Watertown, MA. The company's mission is to revolutionize single-cell biology through accessible, affordable, and scalable solutions for every researcher. Fluent Biosciences aims to accelerate the understanding of biology and disease through its breakthrough pre-templated instant partitions (PipSeq™) technology, which facilitates near-instantaneous self-assembly of individual cells or molecules into millions of uniform partitions without the need for complex instrumentation or expensive consumables. The company was founded in 2018 by Adam Abate, Sepehr Kiani, and Bill Hyun, and Sepehr Kiani has been the CEO since 2018.

Fluent BioSciences, Inc. is a privately funded biotechnology company based in Watertown, MA. The company's mission is to revolutionize single-cell biology through accessible, affordable, and scalable solutions for every researcher. Fluent Biosciences aims to accelerate the understanding of biology and disease through its breakthrough pre-templated instant partitions (PipSeq™) technology, which facilitates near-instantaneous self-assembly of individual cells or molecules into millions of uniform partitions without the need for complex instrumentation or expensive consumables. The company was founded in 2018 by Adam Abate, Sepehr Kiani, and Bill Hyun, and Sepehr Kiani has been the CEO since 2018.

Fluent BioSciences, Inc. is a privately funded biotechnology company based in Watertown, MA. The company's mission is to revolutionize single-cell biology through accessible, affordable, and scalable solutions for every researcher. Fluent Biosciences aims to accelerate the understanding of biology and disease through its breakthrough pre-templated instant partitions (PipSeq™) technology, which facilitates near-instantaneous self-assembly of individual cells or molecules into millions of uniform partitions without the need for complex instrumentation or expensive consumables. The company was founded in 2018 by Adam Abate, Sepehr Kiani, and Bill Hyun, and Sepehr Kiani has been the CEO since 2018.

Mission Bio, Inc. engages in the provision of tools for the study of cellular heterogeneity in human health and life science research. It develops research tools that allow high-throughput, single-cell nucleic acid characterization across a variety of research applications, including oncology and immunology. The company was founded by Charlie Silver, Adam Sciambi, Adam Abate, and Dennis Eastburn on June 29, 2011 and is headquartered in San Francisco, CA.

Fluent BioSciences, Inc. is a privately funded biotechnology company based in Watertown, MA. The company's mission is to revolutionize single-cell biology through accessible, affordable, and scalable solutions for every researcher. Fluent Biosciences aims to accelerate the understanding of biology and disease through its breakthrough pre-templated instant partitions (PipSeq™) technology, which facilitates near-instantaneous self-assembly of individual cells or molecules into millions of uniform partitions without the need for complex instrumentation or expensive consumables. The company was founded in 2018 by Adam Abate, Sepehr Kiani, and Bill Hyun, and Sepehr Kiani has been the CEO since 2018.

Mission Bio, Inc. engages in the provision of tools for the study of cellular heterogeneity in human health and life science research. It develops research tools that allow high-throughput, single-cell nucleic acid characterization across a variety of research applications, including oncology and immunology. The company was founded by Charlie Silver, Adam Sciambi, Adam Abate, and Dennis Eastburn on June 29, 2011 and is headquartered in San Francisco, CA.

Mission Bio, Inc. engages in the provision of tools for the study of cellular heterogeneity in human health and life science research. It develops research tools that allow high-throughput, single-cell nucleic acid characterization across a variety of research applications, including oncology and immunology. The company was founded by Charlie Silver, Adam Sciambi, Adam Abate, and Dennis Eastburn on June 29, 2011 and is headquartered in San Francisco, CA.

Mission Bio, Inc. engages in the provision of tools for the study of cellular heterogeneity in human health and life science research. It develops research tools that allow high-throughput, single-cell nucleic acid characterization across a variety of research applications, including oncology and immunology. The company was founded by Charlie Silver, Adam Sciambi, Adam Abate, and Dennis Eastburn on June 29, 2011 and is headquartered in San Francisco, CA.

Mission Bio, Inc. engages in the provision of tools for the study of cellular heterogeneity in human health and life science research. It develops research tools that allow high-throughput, single-cell nucleic acid characterization across a variety of research applications, including oncology and immunology. The company was founded by Charlie Silver, Adam Sciambi, Adam Abate, and Dennis Eastburn on June 29, 2011 and is headquartered in San Francisco, CA.

Mission Bio, Inc. engages in the provision of tools for the study of cellular heterogeneity in human health and life science research. It develops research tools that allow high-throughput, single-cell nucleic acid characterization across a variety of research applications, including oncology and immunology. The company was founded by Charlie Silver, Adam Sciambi, Adam Abate, and Dennis Eastburn on June 29, 2011 and is headquartered in San Francisco, CA.

Mission Bio, Inc. engages in the provision of tools for the study of cellular heterogeneity in human health and life science research. It develops research tools that allow high-throughput, single-cell nucleic acid characterization across a variety of research applications, including oncology and immunology. The company was founded by Charlie Silver, Adam Sciambi, Adam Abate, and Dennis Eastburn on June 29, 2011 and is headquartered in San Francisco, CA.

Mission Bio, Inc. engages in the provision of tools for the study of cellular heterogeneity in human health and life science research. It develops research tools that allow high-throughput, single-cell nucleic acid characterization across a variety of research applications, including oncology and immunology. The company was founded by Charlie Silver, Adam Sciambi, Adam Abate, and Dennis Eastburn on June 29, 2011 and is headquartered in San Francisco, CA.